Immunoconjugates are antibodies conjugated (joined) to a second molecule, usually a toxin, radioisotope or label. These ... Arming antibodies: prospects and challenges for immunoconjugates. 2005 10 pages. v t e (Articles with short description, Short ... Technology Insight: cytotoxic drug immunoconjugates for cancer therapy. 2007 looks useful from the abstract. Targeted Therapy ... of Cancer: New Prospects for Antibodies and Immunoconjugates. 2006 full article, 18 pages. ...
... (BMS-182248/SGN-15; also known as cBR96-Dox) is an antibody-drug conjugate or (ADC) directed ... "Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates". Science. 261 (5118): 212-5. Bibcode:1993Sci...261.. ...
Safa, Malek; Foon, Kenneth A.; Oldham, Robert K. (2009). "Drug Immunoconjugates". In Oldham, Robert K.; Dillman, Robert O. (eds ...
Damle NK, Frost P (August 2003). "Antibody-targeted chemotherapy with immunoconjugates of calicheamicin". Current Opinion in ...
March 2004). "Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment ... Damle NK, Frost P (August 2003). "Antibody-targeted chemotherapy with immunoconjugates of calicheamicin". Current Opinion in ...
Wu, Anna M.; Senter, Peter D. (7 September 2005). "Arming antibodies: prospects and challenges for immunoconjugates". Nature ...
January 1992). "Immunoconjugates containing novel maytansinoids: promising anticancer drugs". Cancer Research. 52 (1): 127-31. ... Antibody-drug conjugates are an example of bioconjugates and immunoconjugates. ADCs combine the targeting properties of ... March 2004). "Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment ... α emitting immunoconjugates, antibody-conjugated nanoparticles and antibody-oligonucleotide conjugates. As the antibody-drug ...
January 1992). "Immunoconjugates containing novel maytansinoids: promising anticancer drugs" (PDF). Cancer Res. 52 (1): 127-31 ...
... is an immunoconjugate. Arcitumomab is a Fab' fragment of IMMU-4, a murine IgG1 monoclonal ...
"labetuzumab-SN-38 immunoconjugate IMMU-130". National Cancer Institute: NCI Dictionaries. National Institutes of Health, U.S. ...
Cu-labeled immunoconjugates". Nuclear Medicine and Biology. 42 (2): 177-183. doi:10.1016/j.nucmedbio.2014.09.009. ISSN 1872- ...
Cu-labeled immunoconjugates". Nuclear Medicine and Biology. 42 (2): 177-183. doi:10.1016/j.nucmedbio.2014.09.009. ISSN 1872- ...
"Affibody-beta-galactosidase immunoconjugates produced as soluble fusion proteins in the Escherichia coli cytosol". J. Immunol. ...
"Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts". Clinical Cancer Research ...
November 1994). "A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus". The Journal of ... "Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow ...
May 2002). "Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate". Cancer ...
... but also in the preparation of immunoconjugates. EDC is often used in combination with N-hydroxysuccinimide (NHS) for the ...
... a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study". J. ...
... a phase I study of an anti-CD33 calicheamicin immunoconjugate". Blood. 93 (11): 3678-84. doi:10.1182/blood.V93.11.3678. PMID ...
... of metastases was demonstrated after giving injections of NCAM-binding 123J-UJ13a or 131J-UJ13a radio-immunoconjugates to ...
In 2008, Biocon and IATRICa of the United States announced a strategic partnership to co-develop immunoconjugates for targeted ...
Uckun, Fatih M.; Qazi, Sanjive; Dibirdik, Ilker; Myers, Dorothea E. (2012-09-18). "Rational design of an immunoconjugate for ...
In 2006, animal research coupling a murine monoclonal antibody with doxorubicin created an immunoconjugate that was able to ...
... immunoconjugates MeSH D12.776.377.715.548.114.580.450 - immunotoxins MeSH D12.776.377.715.548.114.606 - immunoglobulin ...
... immunoconjugates MeSH D12.776.124.486.485.114.580.450 - immunotoxins MeSH D12.776.124.486.485.114.606 - immunoglobulin ... immunoconjugates MeSH D12.776.124.790.651.114.580.450 - immunotoxins MeSH D12.776.124.790.651.114.606 - immunoglobulin ...
... to his results involving elimination of cancerous tumors and antigens was centered around the use of similar immunoconjugates ...
This study can be performed in vitro (reactivity of the antibody or immunoconjugate should be determined with a quick-frozen ...
Repeated Exposure of Light Enhances the Effect of Immunoconjugate, Bioconjugate Chem., 2012, 23 (3), 604-609 Kobayashi, ...
It is extremely toxic to all cells and, in 2000, a CD33 antigen-targeted immunoconjugate N-acetyl dimethyl hydrazide ...
... cBR96-doxorubicin immunoconjugate - CC-1088 - CC-49 monoclonal antibody - CC-5013 - CC-8490 - CCI-779 - CD34 antigen - CD40- ...